Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript

Arcturus Therapeutics reported Q3 2025 results, revealing a strategic pivot following the indefinite delay of its KOSTAIVE COVID-19 vaccine U.S. BLA filing due to regulatory shifts and market uncertainty. Despite a revenue decline to $17.2 million, the company's cost reduction efforts, including lower R&D expenses, have extended its cash runway into 2028, enabling continued investment in its therapeutic pipeline. Key advancements include promising interim Phase II data for ARCT-032 in cystic fibrosis, showing mucus burden reduction, and plans for H1 2026 regulatory discussions for pivotal trials of ARCT-810 in OTC deficiency.

Analysis

Arcturus Therapeutics reported Q3 2025 results, revealing a strategic pivot driven by the indefinite delay of its KOSTAIVE COVID-19 vaccine U.S. BLA filing due to regulatory shifts and uncertain commercial visibility. This resulted in a $24.5 million year-over-year revenue decrease to $17.2 million, primarily from reduced CSL collaboration activity. However, proactive cost reductions, including a $15.8 million decrease in R&D expenses, extended the company's cash runway into 2028, enabling continued investment in its therapeutic pipeline.

The company highlighted promising interim Phase II data for ARCT-032 in cystic fibrosis, where 10mg daily doses showed general safety and tolerability, with HRCT lung scans revealing mucus burden reductions in four of six Class I CF participants. A 15mg cohort is currently enrolling, and a 12-week study is planned for H1 2026 to further assess efficacy and dose response, with global site expansion aimed at accelerating enrollment.

For ARCT-810 in OTC deficiency, positive interim Phase II data supports regulatory meetings in H1 2026 to discuss pivotal trial strategies for adult and pediatric populations, focusing on glutamine and ammonia as biomarkers, respectively. Additionally, the STARR-sa mRNA platform was validated by positive Phase I data for ARCT-2304, a pandemic A/H5N1 influenza vaccine candidate, demonstrating robust humoral immune responses.

Key Decisions for Investors

• Closely monitor upcoming ARCT-032 data from the 15mg cohort in Q1 2026 and the subsequent 12-week study initiation in H1 2026, as these are critical for validating the CF program's efficacy and dose selection.
• Pay attention to the H1 2026 regulatory alignment meetings for ARCT-810, as clarity on pivotal trial design and biomarkers will significantly de-risk the OTC program and define its path to market.
• Assess the long-term financial implications of the KOSTAIVE U.S. BLA delay, despite the extended cash runway into 2028, and evaluate the company's strategy for sustained funding of its core therapeutic pipeline.